Twelve CHD patients received weekly intravenous (IV) REP 2139-Ca (500 mg) for 15 weeks followed by 15 weeks of IV REP 2139-Ca (250 mg) combined with PEG IFN-α and finally, PEG IFN-α alone for 33 weeks. Here, IFNA1 is linked to coronary artery disorder.